The Harvard Stem Cell Institute is developing new therapies to repair kidney damage, reducing the need for dialysis and transplantation.
Diabetes is a corrosive illness. The imbalance of blood sugar causes small changes in the body that slowly lead to blurry vision, skin rashes, and damaged nerves. In serious cases, diabetes wears away the path of blood to the kidneys, causing eventual organ failure. In fact, half of all kidney failures in the United States are caused by diabetes. For the majority of patients who end up on the waiting list for a kidney transplant, a diagnosis of kidney failure means a choice between dialysis and certain death.
Dialysis costs both time and money. Most patients must drive to a dialysis center three times per week to be hooked up to a machine for four hours per session. The annual costs for this treatment are about $80,000 per patient and rising. The total amount of private and public funds spent on the procedure will soon reach $50 billion per year. A single kidney transplant is equivalent in cost to about two-and-a-half years of dialysis, but it usually takes three years to find an available donor match.
The Harvard Stem Cell Institute (HSCI) Kidney Group has short, medium, and long-term strategies to develop new therapies for diabetes-related kidney damage (diabetic nephropathy). This multi-pronged approach aims to capitalize on promising translational achievements in the near future, while pursing potential drugs and the ultimate goal of creating an entirely artificial kidney using stem cells.
Mesenchymal stem cells are the bodys natural defense against kidney damage. Found in the bone marrow, these stem cells protect the kidneys from injury and accelerate healing. Harvard Stem Cell Institute scientists have identified protein candidates secreted from mesenchymal stem cells that may be administered independently to aid in kidney repair. In another approach, mesenchymal stem cells are being incorporated into miniature dialysis machines that expose the patients blood to these cells, allowing pro-repair proteins to be delivered directly to the kidneys.
Having identified the kidney cell types that are most susceptible to injury during diabetes, the HSCI Kidney Group now plans to target them with new drugs. In order to screen for potential drug targets, researchers must first identify genes that change in diabetic kidney cells, and then identify compounds that slow or stop the destructive gene expression. A drug for disease-related kidney damage has the potential to eliminate the need for dialysis.
The project with the greatest potential impact on diabetes patients is HSCIs large, multi-disciplinary effort to create an artificial kidney using stem cells and nanotechnology.
The functional unit of the kidney is a nephron a long tube that filters blood at one end and then turns that filtrate into urine. HSCI scientists plan to isolate kidney stem cells, mix them with soluble gels, and mold them into the architecture of a nephron. Scientists have already successfully created an artificial rat kidney that produces urine once transplanted into the animal, making artificial organ transplantation a highly possible reality for humans.
HSCI Kidney Program Leader Benjamin Humphreys, MD, PhD, at Brigham and Women's Hospital answers patient frequently asked questions about kidney disease and stem cells.
See the article here:
Kidney Disease | Harvard Stem Cell Institute (HSCI)
- Hannah just thought she was being clumsy, but her bruises were a sign she needed to see her doctor - Daily Mail - October 27th, 2023
- Brent Rutemiller's Cancer In Early Remission After 42 Weeks of Chemotherapy and Stem Cell Transplant - Swimming World Magazine - May 20th, 2022
- Other Notable Health Studies & Research From May 17, 2022 - Study Finds - May 20th, 2022
- Clinton County Relay For Life holds annual event in Riverview Park - Lock Haven Express - May 20th, 2022
- Illinois Is Being Invaded By Worms That Jump A Foot In The Air - 1440wrok.com - May 20th, 2022
- Moderna, J&J COVID Booster Shots Near Authorization. Here's What to Know - NBC Chicago - October 26th, 2021
- GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF- R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research -... - October 26th, 2021
- Merck Provides Update on KEYTRUDA (pembrolizumab) Indication in Third-Line Gastric Cancer in the US - Business Wire - July 6th, 2021
- Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene - GlobeNewswire - July 6th, 2021
- New global guidelines for stem cell research aim to drive discussions, not lay down the law - The Conversation AU - May 27th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 27th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 27th, 2021
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 27th, 2021
- OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for... - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Opdivo in Combination with Cabometyx Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced RCC -... - February 14th, 2021
- Astellas and Seagen Announce Presentation of Results from PADCEV (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced... - February 14th, 2021
- [Full text] Loganin Attenuates Septic Acute Renal Injury with the Participation of | DDDT - Dove Medical Press - February 14th, 2021
- [Full text] Encephalopathy Induced by Preventive Administration of Acyclovir in a | IJGM - Dove Medical Press - February 14th, 2021
- Joint inflammation: Causes, treatment, and symptoms - Medical News Today - February 14th, 2021
- Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity - PRNewswire - February 3rd, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 3rd, 2021
- Mini kidneys bioprinted in the lab - Lab + Life Scientist - December 4th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - December 4th, 2020
- News briefing: Four biotechs announce IPO terms, setting the pace to round out a busy year; FDA sets PDUFA date for Kadmon's graft-versus-host drug -... - December 4th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - December 4th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 11th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 11th, 2020
- Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 - Investing News Network - November 11th, 2020
- The great reset: new danger on the horizon - Amandala - November 11th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 11th, 2020
- COVID Drug Given to Trump Developed From Aborted Fetus Cells - Quint Fit - October 10th, 2020
- Lars Jaeger: The Future is Veggie, With 3D Printing - finews.asia - October 10th, 2020
- Laid off from ImmunoGen, an ex-Genzyme and Shire exec heads to an ARCH upstart - Endpoints News - October 10th, 2020
- 5 Deadly Pre-existing Conditions You Could Have Due To COVID-19 - Brumpost - Brumpost - October 10th, 2020
- The Crypto Daily Movers and Shakers October 10th, 2020 - Sports Grind Entertainment - October 10th, 2020
- Coronavirus Tracker: Bexar Co. cases surpass 59,000; Texas hospitalizations trending in the wrong direction - KENS5.com - October 10th, 2020
- Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million - Business Wire - September 24th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 15th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - Business Wire - September 15th, 2020
- Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma - OncLive - September 9th, 2020
- Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients - GlobeNewswire - September 9th, 2020
- ASX Biotechs Surfing The Covid Story - FN Arena News - August 16th, 2020
- Merck and Eisai Receive Complete Response Letter for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination as First-Line Treatment for... - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma - Business... - July 10th, 2020
- Coronavirus PPP Loans In Livingston: Where The Money Went - Livingston, NJ Patch - July 9th, 2020
- Stem Cell Therapy For Kidney Failure. Learn More Now ... - July 7th, 2020
- Anemia in chronic kidney disease - kidneyfund.org - July 7th, 2020
- Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead - July 7th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer -... - June 30th, 2020
- R3 International Offering Stem Cell Therapy Program for Anti Aging in Mexico - PR Web - June 30th, 2020
- Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - Stockhouse - June 30th, 2020
- FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that... - June 25th, 2020
- Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System - Business Wire - June 25th, 2020
- First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times - May 27th, 2020
- Scientists generate millions of mature human cells, far more than have ever been produced - UB News Center - May 20th, 2020
- Heres The Reason Why Scientists Are Growing Human Cells In Mouse Embryo - Medical Daily - May 20th, 2020
- Cell therapies trial planned for COVID-19 - Mirage News - May 5th, 2020
- New Study Finds That Wearing Contact Lenses Doesn't Increase Risk of COVID-19 Infection - HealthDay Coronavirus Liveblog - April 26th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 15th, 2020
- Stem Cells and Chronic Kidney Disease | Mayo Clinic Center ... - April 11th, 2020
- Kidney Failure | Stem Cell Treatment in Tijuana Mexico - April 11th, 2020
- MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND... - April 11th, 2020
- Merck Receives Priority Review from FDA for Second Application for KEYTRUDA (pembrolizumab) Based on Biomarker, Regardless of Tumor Type - Benzinga - April 11th, 2020
- A coronavirus vaccine is being developed in record time. But dont expect that technology to speed up flu vaccines yet. - Columbia Daily Herald - April 7th, 2020
- Researchers test drug that stops early stages of COVID-19 - Open Access Government - April 7th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- Made-in-space organs could soon be reality - ETHealthworld.com - March 13th, 2020
- What Is the Coronavirus? - WIRED - March 6th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 25th, 2020
- Coronavirus: Doctors try 3,000-year-old Traditional Chinese Medicine (TCM) to treat the virus - Times of India - February 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for... - February 14th, 2020
- Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy... - February 14th, 2020
- Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha - February 10th, 2020
- Cambridge Science Festival showcases new research at the forefront of healthcare and medicine - Cambridge Network - February 10th, 2020
- Anemia: Causes, symptoms and treatment - Livescience.com - February 8th, 2020
- 4 Crazy but Effective Ways to Save More Money This Year - Nasdaq - February 4th, 2020
- BAME lives to be saved as new organ donation law rolls out - Keep the Faith - January 15th, 2020
- HIV drug resistance an emerging threat, expert warns - DAWN.com - January 10th, 2020
- A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org - January 10th, 2020